Nuplazid, med for hallucinations associated with Parkinson's disease

October 30, 2018

FDA Finds No Unexpected Safety Risk With Pimavanserin 
September 24, 2018   

Additional Neurology Topics, Alzheimer's/Other Dementias, Psychotic Disorders

 

The Food and Drug Administration (FDA) recently completed an extensive review of all postmarking reports of serious adverse events (SAEs) and deaths linked to the use of Nuplazid (pimavanserin). Based on analysis of available data, the FDA did not identify any novel or surprising safety findings, or evidence that is inconsistent with the established safety profile currently listed in the drug label. The FDA’s conclusion remains unchanged, that the drug's benefits outweigh risks for patients with hallucinations and delusions attributed to Parkinson’s disease psychosis. The FDA conducted a comprehensive analysis of information submitted to the FDA Adverse Event Reporting System (FAERS), drug utilization data, safety data from the Nuplazid new drug application, the sponsor’s Periodic Adverse Drug Experience Reports, the sponsor’s analysis of fatal adverse event reports with Nuplazid, and published medical literature. While Nuplazid and other antipsychotics have a Boxed Warning suggesting increased risk of death in elderly patients with dementia-related psychosis associated with the use of these drugs, the FDA concluded that patients with Parkinson’s disease psychosis have a higher mortality rate due to their older age, advanced Parkinson’s disease, and other medical conditions. In the FAERS reports that included cause of death, there was no evident pattern to suggest a drug effect. Patients taking Nuplazid for Parkinson’s disease psychosis are encouraged to continue use, as prescribed by their health care provider. The FDA continues to monitor Nuplazid-associated adverse events and will update the public as necessary.

Please reload

Our Recent Posts

"Anna-Sophie Rommel, Veerle Bergink, Xiaoqin Liu, Trine Munk-Olsen, Nina Maren Molenaar

Journal of Clinical Psychiatry 2020 May 12, 81 (3)

OBJECTIVE: Re...

"Long-Term Effects of Intrauterine Exposure to Antidepressants on Physical, Neurodevelopmental, and Psychiatric Outcomes: A Systematic Review&quo...

May 21, 2020

Below is an updated consent for telehealth; you can obtain the official form from my assistant Eric Scott Kincaid.  I added in the following (listed a...

Updated Consent for Telehealth

March 24, 2020

Hi everyone,

I know you’re all closely watching the new developments in the COVID-19 pandemic and I imagine you’ve seen the recent guidelines that sugg...

COVID-19/coronavirus update

March 15, 2020

1/1
Please reload

Tags

I'm busy working on my blog posts. Watch this space!

Please reload

 

mark@markwwilsonmdpc.com

assistant@markwwilsonmdpc.com

(917) 441-2344

PayPal can be used to send payment for services:

©2018 by Mark W. Wilson, MD, PC. Proudly created with Wix.com